<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Loutan L</dc:creator>
  <dc:creator>Bovier P</dc:creator>
  <dc:creator>Althaus B</dc:creator>
  <dc:creator>Glück R</dc:creator>
  <dc:date>1994</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Immunopotentiating reconstituted influenza virosomes (IRIV) are efficient carrier systems for small virion particles such as hepatitis A virus (HAV). We evaluated immunogenicity and tolerability of an IRIV-HAV vaccine and the effectiveness of a booster by immunising 104 healthy HAV seronegative volunteers. A single dose was highly immunogenic, since 98% of volunteers had seroconverted after 2 weeks. Anti-HAV titres remained high, with 100% seroconversion rate 1 year later, when the booster was given. The vaccine was effective, with a 22-fold increase in geometric mean titres 1 month later. No serious adverse reactions were observed.</dc:description>
  <dc:identifier>https://sonar.ch/global/documents/152367</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/s0140-6736(94)91162-2</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/7905144</dc:relation>
  <dc:source>Lancet (London, England). - 1994</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Adjuvants, Immunologic</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Adult</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">Antibodies, Viral</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">Drug Carriers</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">Enzyme-Linked Immunosorbent Assay</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">Female</dc:subject>
  <dc:subject xmlns:ns7="xml" ns7:lang="en">Hepatitis A</dc:subject>
  <dc:subject xmlns:ns8="xml" ns8:lang="en">Hepatitis A Virus, Human</dc:subject>
  <dc:subject xmlns:ns9="xml" ns9:lang="en">Humans</dc:subject>
  <dc:subject xmlns:ns10="xml" ns10:lang="en">Immunization, Secondary</dc:subject>
  <dc:subject xmlns:ns11="xml" ns11:lang="en">Influenza A virus</dc:subject>
  <dc:subject xmlns:ns12="xml" ns12:lang="en">Male</dc:subject>
  <dc:subject xmlns:ns13="xml" ns13:lang="en">Vaccines, Inactivated</dc:subject>
  <dc:subject xmlns:ns14="xml" ns14:lang="en">Vaccines, Synthetic</dc:subject>
  <dc:subject xmlns:ns15="xml" ns15:lang="en">Viral Hepatitis Vaccines</dc:subject>
  <dc:subject xmlns:ns16="xml" ns16:lang="en">Virion</dc:subject>
  <dc:title xmlns:ns17="xml" ns17:lang="en">Inactivated virosome hepatitis A vaccine.</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
